SCHEMBL3243070

SCHEMBL3243070

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)NCC4CCNCC4)cc3c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR4 Q13639 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
MAPT P10636 5/20 0.37
TP53 P04637 3/20 0.37
LMNA P02545 3/20 0.37
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP2C9 P11712 2/20 0.37
THRB P10828 1/20 0.36
POLB P06746 5/20 0.36
HSD17B10 Q99714 2/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
KDM4E B2RXH2 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GABRA1 P14867 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14877668 0.95 MAPT (0.36) HTR4MAPTTP53LMNAMEN1
SCHEMBL3250683 0.95 MAPT (0.36) HTR4MAPTTP53LMNAMEN1
SCHEMBL3254905 0.88 PARG (0.45) MAPTTP53LMNAMEN1KMT2A
SCHEMBL3245352 0.88 HTR2C (0.42) HTR4HTR2CHTR2BMEN1KMT2A
SCHEMBL3249464 0.87 HTR2C (0.38) HTR4HTR2CHTR2BMAPTTP53
SCHEMBL3250602 0.85 PARG (0.50) MAPTTP53LMNAMEN1KMT2A
SCHEMBL3248963 0.83 TAS2R14 (0.44) MAPTTP53LMNAMEN1KMT2A
SCHEMBL3248398 0.83 POLB (0.40) HTR4HTR2CHTR2BMEN1KMT2A
SCHEMBL3250055 0.82 POLB (0.43) HTR2CHTR2BMEN1KMT2AALDH1A1
SCHEMBL3247256 0.82 TDP1 (0.53) MAPTTP53LMNAALDH1A1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 HTR4 4699/4885HTR2C 3682/4885HTR2B 4297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.